How One Drug Wiped Out 99% Of India's Vultures In Less Than 20 Years
Translation Desk
Last Updated: May 28, 2025, 16:21 IST
Ingesting traces of Diclofenac caused acute kidney failure in vultures, but despite its ban in India in 2006, illegal use persists. (News18)
Once a common sight circling above carcasses, vultures have all but vanished from India's skies. Research by the University of Chicago revealed that between 1990 and 2007, 99% of the vulture population in India perished.
This collapse has had dire consequences: in the absence of these natural scavengers, infections from decaying animal carcasses have spread, reportedly contributing to five lakh human deaths. The Diclofenac Disaster
The principal culprit behind this ecological tragedy is the veterinary drug Diclofenac, commonly used in the 1990s to treat livestock. Though effective, Diclofenac residues in cattle carcasses proved lethal to vultures.
Ingesting even trace amounts caused acute kidney failure in the birds. Despite India banning the drug in 2006, its illegal use still persists. Alarming Decline Rates
India was once home to an estimated 40 to 50 million vultures. By 2007, that number had dropped catastrophically. Populations of: White-rumped vultures (Gyps bengalensis) declined by 99.9%
declined by 99.9% Indian vultures (Gyps indicus) by 95%
by 95% Slender-billed vultures (Gyps tenuirostris) by 97%
This marks one of the fastest recorded declines of any bird species in history. WWF India Poster Threats Beyond Diclofenac
Even after the ban, vulture populations have not rebounded. Vultures breed slowly, laying just one egg annually, and face numerous other threats including: Electrocution from power lines
Collisions with wind turbines
Injuries from kite strings
Their absence has triggered a rise in feral dog and crow populations, increasing the risk of rabies and other zoonotic diseases. Cultural And Economic Fallout
Swipe Left For Next Video View all
The decline also impacts cultural practices. The Parsi community, which conducts sky burials dependent on vulture scavenging, has had to alter funeral rites. The economic toll is staggering too. Between 2000 and 2005, losses due to vulture extinction were estimated at $69.4 billion annually, affecting industries like leather production.
Since 2016, India has undertaken conservation efforts, including the reintroduction of protected vulture species into the wild. However, experts stress that community engagement and stringent enforcement of Diclofenac bans are critical for reversing this crisis. News lifestyle How One Drug Wiped Out 99% Of India's Vultures In Less Than 20 Years
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
23 minutes ago
- Hans India
Every 3rd Indian affected by some metabolic dysfunction, mass level awareness needed: Minister
Every third Indian is affected by some metabolic dysfunction, said Union Minister Dr Jitendra Singh, while proposing a mass campaign for the prevention of Type 2 diabetes in the young. Addressing the Foundation Day ceremony of the Research Society for Study of Diabetes in India (RSSDI), Singh expressed concern that India continues to be labelled the 'diabetes capital of the world'. 'Every third Indian is affected by some form of metabolic dysfunction,' he said. The Minister, himself a globally renowned endocrinologist, also cautioned against diabetes disinformation, which tends to be spread, sometimes inadvertently, from certain quarters. He debunked popular myths, such as the belief in 'one meal a day', urging for a more scientific understanding of meal quality and quantity in diabetes care. Singh reiterated the target of reducing non-communicable diseases (NCDs) by 10 per cent, particularly those associated with fatty liver, visceral fat, and obesity. He emphasised that public health messaging must go beyond medical publications and into institutionalised outreach to common citizens. Calling for evidence-based health awareness, Singh gave a firm dictum: 'Treat diabetes before it occurs, stressing that prevention is better than cure'. Recently, Singh also launched a study led by RSSDI, which showed that yoga can reduce the risk of diabetes by 40 per cent, highlighting the potential of yoga in preventive healthcare. The study suggested that the regular practice of yoga may reduce the risk of developing Type 2 diabetes by as much as 40 per cent in individuals predisposed to the condition. "This is one of the first such efforts that seeks to scientifically document the prevention of the occurrence of Type 2 diabetes with yoga. As per the authors of the report, there is as much as a 40 per cent reduction in the development of Type 2 diabetes among potential individuals who practice yoga regularly," Singh said.
New Indian Express
35 minutes ago
- New Indian Express
Agilent opens its Indian biopharma capability center in Hyderabad
CHENNAI: Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its new Biopharma Capability Center in Hyderabad. The facility represents a significant investment in India's expanding life sciences ecosystem and aligns with the U.S.-based company's broader three-to-five-year growth strategy for the country. The center was inaugurated by Telangana's Minister for Information Technology, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the presence of Agilent's global CEO Padraig McDonnell. Designed to support the entire drug development process, the center features advanced laboratory technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines. It will serve as a hub for innovation and collaboration, focusing on the development of biologics, biosimilars, and precision medicine. The facility offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics. These capabilities allow companies to simulate real laboratory environments, test for quality and compliance, and co-create solutions tailored to both Indian and global markets. For Hyderabad's biopharma startups, academic institutions, and skilled professionals, the center provides access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports accelerated R&D, hands-on training aligned with international regulatory standards, and fosters stronger industry-academia collaboration. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO of Agilent Technologies. 'Our future will be shaped by continued innovation and a relentless focus on our customers.' 'This new experience center reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions,' McDonnell added. Commenting on the launch, Minister Sridhar Babu said, 'With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The Agilent Biopharma Experience Center is a significant milestone that strengthens Telangana's position as a global life sciences leader and adds value to our growing innovation-driven ecosystem.' Telangana currently accounts for nearly one-third of India's pharmaceutical production and 40% of bulk drug exports. Hyderabad boasts one of the most mature and future-focused life sciences ecosystems in India, with deep industry expertise, strong R&D capabilities, and a conducive policy environment. Building on the city's legacy in generics and increasing emphasis on advanced therapies, the new center adds cutting-edge analytical and regulatory capabilities that support local innovation and global delivery. Earlier this year, Agilent also launched its India Solution Center in Manesar. With this expansion, the company is deepening customer partnerships and positioning India as a strategic hub in its global innovation and growth roadmap. 'Agilent is already working closely with many of India's leading biopharma companies,' McDonnell said. 'With this center, we aim to strengthen those relationships and co-create solutions that address the evolving needs of both Indian and global markets.'
News18
an hour ago
- News18
Two Arunachal districts secure top position in PMMVY enrollment
Itanagar, Jul 30 (PTI) Arunachal Pradesh has made significant strides in the implementation of the Pradhan Mantri Matru Vandana Yojana (PMMVY), with Anjaw and Pakke Kessang districts securing the top two positions nationally in percentage enrollment progress. According to the latest report of the Union Women and Child Development ministry, released on July 25, Anjaw district achieved a remarkable 354 per cent of its indicative enrollment target, ranking first in India. Pakke Kessang followed closely with 313 per cent, placing second nationwide. The progress has propelled Arunachal Pradesh's overall performance in the PMMVY rankings, lifting the state from the bottom tier to the 6th position among all states and union territories. Other districts of the state showing strong performance include Lower Dibang Valley (147%), Lower Siang (114%), and East Siang (61%), all of which have exceeded their set targets. However, districts such as Shi-Yomi, Lower Subansiri, and Leparada reported less than 10% progress, prompting officials to intensify outreach and registration efforts in those areas. The Pradhan Mantri Matru Vandana Yojana (PMMVY), a centrally sponsored flagship scheme by the Women and Child Development ministry is designed to support pregnant women and lactating mothers. The scheme is to provide maternity benefits to women belonging to socially and economically disadvantaged sections of society. The maternity benefit is to be provided to a woman for the first two living children, provided the second child is a girl. With renewed focus on grassroots implementation and awareness campaigns, state authorities remain optimistic about closing the gaps and ensuring full coverage across all 28 districts. PTI UPL UPL RG view comments First Published: July 30, 2025, 12:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
